Semper Paratus Acquisition Corp TVGNW

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
33/100
Developing

Ranked against 712 peers in Biotechnology

About Semper Paratus Acquisition Corp

Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer … Full TVGNW analysis →

Key risks

  • Elevated Debt Risk Debt serviceability is weak (score 0.23), raising refinancing risk.
  • Liquidity Concerns Liquidity is concerning (score 0.03), raising questions about short-term obligations.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Insufficient Data
—
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where TVGNW ranks in Biotechnology

Semper Paratus Acquisition Corp ranks #470 of 713 scored companies in Biotechnology by moat score — the top 66%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
466 Psyence Biomedical Ltd. Warrant PBMWW 33/100 Developing
467 Trevena, Inc. TRVN 33/100 Developing
468 Adial Pharmaceuticals, Inc ADIL 33/100 Developing
469 Lixte Biotechnology Holdings, I LIXTW 33/100 Developing
470 Semper Paratus Acquisition Corp TVGNW 33/100 Developing
471 Biomea Fusion, Inc. BMEA 33/100 Developing
472 PMGC Holdings Inc. ELAB 33/100 Developing
473 Lisata Therapeutics, Inc. LSTA 33/100 Developing
474 Candel Therapeutics, Inc. CADL 33/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How TVGNW scores on the Corporate Default defenses

Pricing Power

Not measurable · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Not measurable · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Not measurable · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 56 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 16 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Not measurable · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding TVGNW's moat

What is Semper Paratus Acquisition Corp's moat score?

Semper Paratus Acquisition Corp (TVGNW) scores 33 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #470 of 713 scored companies in Biotechnology, the top 66%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Capital Efficiency (56/100) and its weakest is Resilience (16/100).

How does Semper Paratus Acquisition Corp compare with other Biotechnology companies?

Semper Paratus Acquisition Corp ranks #470 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Lixte Biotechnology Holdings, I (LIXTW) at 33 just above it and Biomea Fusion, Inc. (BMEA) at 33 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Semper Paratus Acquisition Corp scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Semper Paratus Acquisition Corp?

The Corporate Default template measures 6 defenses, and TVGNW scores: Pricing Power (not measurable), Cost Advantage (not measurable), Customer Stickiness (not measurable), Capital Efficiency (56), Resilience (16), Scale & Market Position (not measurable). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000